1. |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263.
|
2. |
Oudkerk M, Liu S, Heuvelmans MA, et al. Lung cancer LDCT screening and mortality reduction—Evidence, pitfalls and future perspectives. Nat Rev Clin Oncol, 2021, 18(3): 135-151.
|
3. |
National lung screening trial research team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011, 365(5): 395-409.
|
4. |
Boiselle PM. Computed tomography screening for lung cancer. JAMA, 2013, 309(11): 1163-1170.
|
5. |
Crosby D, Bhatia S, Brindle KM, et al. Early detection of cancer. Science, 2022, 375(6586): eaay9040.
|
6. |
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell, 2011, 144(5): 646-674.
|
7. |
Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discov, 2022, 12(1): 31-46.
|
8. |
Aberle DR, DeMello S, Berg CD, et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med, 2013, 369(10): 920-931.
|
9. |
Mittal D, Gubin MM, Schreiber RD, et al. New insights into cancer immunoediting and its three component phases—Elimination, equilibrium and escape. Curr Opin Immunol, 2014, 27: 16-25.
|
10. |
Sullivan FM, Farmer E, Mair FS, et al. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): Study protocol for a randomized controlled trial. BMC Cancer, 2017, 17(1): 187.
|
11. |
Ren S, Zhang S, Jiang T, et al. Early detection of lung cancer by using an autoantibody panel in Chinese population. Oncoimmunology, 2017, 7(2): e1384108.
|
12. |
DeVita VT, Young RC, Canellos GP. Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. Cancer, 1975, 35(1): 98-110.
|
13. |
Ehx G, Perreault C. Discovery and characterization of actionable tumor antigens. Genome Med, 2019, 11(1): 29.
|
14. |
Finn OJ. Human tumor antigens yesterday, today, and tomorrow. Cancer Immunol Res, 2017, 5(5): 347-354.
|
15. |
Massion PP, Healey GF, Peek LJ, et al. Autoantibody signature enhances the positive predictive power of computed tomography and nodule-based risk models for detection of lung cancer. J Thorac Oncol, 2017, 12(3): 578-584.
|
16. |
Wang W, Zhuang R, Ma H, et al. The diagnostic value of a seven-autoantibody panel and a nomogram with a scoring table for predicting the risk of non-small-cell lung cancer. Cancer Sci, 2020, 111(5): 1699-1710.
|
17. |
He T, Wu Z, Xia P, et al. The combination of a seven-autoantibody panel with computed tomography scanning can enhance the diagnostic efficiency of non-small cell lung cancer. Front Oncol, 2022, 12: 1047019.
|
18. |
Patel AJ, Tan TM, Richter AG, et al. A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications. Br J Cancer, 2022, 126(2): 238-246.
|
19. |
Chen SS, Li K, Wu J, et al. Stem signatures associated antibodies yield early diagnosis and precise prognosis predication of patients with non-small cell lung cancer. J Cancer Res Clin Oncol, 2021, 147(1): 223-233.
|
20. |
Li Y, Li CQ, Guo SJ, et al. Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma. EBioMedicine, 2020, 53: 102674.
|
21. |
Li S, Ma Y, Xiong Y, et al. Five tumor-associated autoantibodies expression levels in serum predict lung cancer and associate with poor outcome. Transl Cancer Res, 2019, 8(4): 1364-1373.
|